3. The FDA has approved trastuzumab deruxtecan (Enhertu, AstraZeneca and Daiichi Sankyo) for adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow breast cancer that has ...

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...

Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan. Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast ...

The results suggest that AZ and Daiichi Sankyo could be in line for a second big win for a cancer ADC to follow Enhertu (trastuzumab deruxtecan), their HER2-directed drug which has just claimed a ...

Their original ADC, called Enhertu (trastuzumab deruxtecan), secured its seventh FDA indication on Jan. 27. The approval clears Enhertu for treating patients with HER2-low or HER2-ultralow metastatic ...

Every image on iStock falls into one of two collections. Our Essentials collection gives you the everyday content you need, while our Signature library features our best quality, premium handpicked ...

You can now upload your own images to use with our AI‑powered tools: Place an uploaded product shot into any scene you can imagine. Use your own photo or illustration as a reference image for image‑to ...

fDivision of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Via Mariano Semmola 52, Naples 80131, Italy gDepartment of Medicine, University of Udine, Via Palladio 8, ...

HEALTH workers in Sogeri, Central Province, now have a safe space to live while serving the rural community, thanks to a joint partnership that saw the completion of a three-bedroom house recently.